<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-569
Date of Submission: 2024-12-28

This report was submitted by a Physician from Hogan LLC Medical Center concerning patient ANON-PX-2799. The subject is a 31-year-old male with a significant medical history including coronary artery disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Warfarin administered via the Oral route at a dosage of 169mg, initiated on 2024-10-13 for Thromboembolism prevention with the course ongoing; Sertraline administered via the Subcutaneous route at a dosage of 442mg, initiated on 2024-10-13 for Major depressive disorder with the course ongoing.

On approximately 2024-10-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Anaphylaxis. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Car interest which experience perform rise include. Much like product president increase.</data>
report_id: ADR-2024-569
report_date: '2024-12-28'
patient_details:
  patient_id: ANON-PX-2799
  gender: Male
  relevant_history:
  - coronary artery disease
  - anxiety
  age_at_reaction: 31
suspected_drugs:
- drug_name: Warfarin
  dosage: 169mg
  route_of_administration: Oral
  start_date: '2024-10-13'
  indication_for_use: Thromboembolism prevention
- drug_name: Sertraline
  dosage: 442mg
  route_of_administration: Subcutaneous
  start_date: '2024-10-13'
  indication_for_use: Major depressive disorder
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2024-10-28'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2024-10-28'
  severity: Mild
  outcome: Unknown
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 5
reporting_facility: Hogan LLC Medical Center
reporter_type: Physician
notes: Car interest which experience perform rise include. Much like product president
  increase.
